open access

Vol 5, No 3 (2016)
Original articles (submitted)
Published online: 2016-09-06
Get Citation

Efficacy and safety of Glycebal (PDM011011) capsules as adjuvant therapy in subjects with type 2 diabetes mellitus: an open label, randomized, active controlled, phase II trial

Ashish C. Suthar, Anand Deshmukh, Vijaya Babu, Vijaya S. Mohan, Madhukar V. Chavan, Dutta Kumar, Vijaysingh Chauhan, Somesh Sharma, Mahesh Sharma
DOI: 10.5603/DK.2016.0015
·
Clinical Diabetology 2016;5(3):88-94.

open access

Vol 5, No 3 (2016)
Original articles (submitted)
Published online: 2016-09-06

Abstract

Background. Momordica charantia is a medicinal plant used traditionally for treatment of various diseases including diabetes.
Objective. To evaluate the efficacy and safety of PDM011011 capsules (1.2 g/day) as an adjuvant therapy in subjects with type 2 diabetes mellitus (T2DM).
Methods. Each PDM011011 capsule contained 400 mg dry fruit juice powder of Momordica charantia. Ninety three T2DM patients receiving at least one oral hypoglycemic treatment were screened. The eligible 85 subjects were randomized into 3:1 ratio in drug treatment (PDM011011 capsules) and placebo arm. Sixty-four patients received three 400 mg PDM011011 capsules (1.2 g/day) while 21 patients received three placebo capsules per day for 90 days respectively. The primary efficacy endpoints were mean change in FPG, PPG level and HbA1c% from baseline to day 30, 60 and 90 after interventions.
Results. PDM011011-capsule (1.2 g/day) showed significant reduction in FPG level by 14.59% after 90 days treatment, while patients receiving placebo capsules exhibited a marginal increase of 2.12%. The reduction in FPG level was statistically significant (p = 0.013) as compared with the placebo group. It also reduced PPG level by 22.21% as compared to the 3.71% reduction (p = 0.002) in placebo group. The encouraging reduction in HbA1c% in the drug group was 0.78 as compared to the placebo group with only 0.20 (p = 0.066). PDM011011 capsule showed no adverse events, serious adverse events and death in the study population.
Conclusion. PDM011011-capsule (1.2 g/day) showed good efficacy and safety; and it can be prescribed as an adjuvant therapy in subjects with T2DM.

Abstract

Background. Momordica charantia is a medicinal plant used traditionally for treatment of various diseases including diabetes.
Objective. To evaluate the efficacy and safety of PDM011011 capsules (1.2 g/day) as an adjuvant therapy in subjects with type 2 diabetes mellitus (T2DM).
Methods. Each PDM011011 capsule contained 400 mg dry fruit juice powder of Momordica charantia. Ninety three T2DM patients receiving at least one oral hypoglycemic treatment were screened. The eligible 85 subjects were randomized into 3:1 ratio in drug treatment (PDM011011 capsules) and placebo arm. Sixty-four patients received three 400 mg PDM011011 capsules (1.2 g/day) while 21 patients received three placebo capsules per day for 90 days respectively. The primary efficacy endpoints were mean change in FPG, PPG level and HbA1c% from baseline to day 30, 60 and 90 after interventions.
Results. PDM011011-capsule (1.2 g/day) showed significant reduction in FPG level by 14.59% after 90 days treatment, while patients receiving placebo capsules exhibited a marginal increase of 2.12%. The reduction in FPG level was statistically significant (p = 0.013) as compared with the placebo group. It also reduced PPG level by 22.21% as compared to the 3.71% reduction (p = 0.002) in placebo group. The encouraging reduction in HbA1c% in the drug group was 0.78 as compared to the placebo group with only 0.20 (p = 0.066). PDM011011 capsule showed no adverse events, serious adverse events and death in the study population.
Conclusion. PDM011011-capsule (1.2 g/day) showed good efficacy and safety; and it can be prescribed as an adjuvant therapy in subjects with T2DM.

Get Citation

Keywords

type 2 diabetes mellitus, Momordica charantia, Glycebal, PDM011011 capsule, hypoglycemic, antidiabetic

About this article
Title

Efficacy and safety of Glycebal (PDM011011) capsules as adjuvant therapy in subjects with type 2 diabetes mellitus: an open label, randomized, active controlled, phase II trial

Journal

Clinical Diabetology

Issue

Vol 5, No 3 (2016)

Pages

88-94

Published online

2016-09-06

DOI

10.5603/DK.2016.0015

Bibliographic record

Clinical Diabetology 2016;5(3):88-94.

Keywords

type 2 diabetes mellitus
Momordica charantia
Glycebal
PDM011011 capsule
hypoglycemic
antidiabetic

Authors

Ashish C. Suthar
Anand Deshmukh
Vijaya Babu
Vijaya S. Mohan
Madhukar V. Chavan
Dutta Kumar
Vijaysingh Chauhan
Somesh Sharma
Mahesh Sharma

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl